We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+0.45%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.08B
AUM Growth
-$169M
Cap. Flow
-$29.6M
Cap. Flow %
-1.42%
Top 10 Hldgs %
77.47%
Holding
49
New
4
Increased
17
Reduced
7
Closed
2

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$61.2M
2
EPZM
Epizyme, Inc
EPZM
+$41.5M
3
AMAG
AMAG Pharmaceuticals
AMAG
+$36.3M
4
KPTI icon
Karyopharm Therapeutics
KPTI
+$24.1M
5
UTHR icon
United Therapeutics
UTHR
+$13.5M

Top Sells

Rank Stock Value
1
THOR
THORATEC CORPORATION
THOR
+$136M
2
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$68.4M
3
CYBX
CYBERONICS INC
CYBX
+$24.5M
4
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
+$12.3M
5
ENDP
Endo International plc
ENDP
+$5.07M

Sector Composition

Rank Sector Weight
1 Healthcare 72.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAC
1
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$304M 14.6%
2,579,154
-523,873
-17% -$68.4M
CLVS
2
DELISTED
Clovis Oncology, Inc.
CLVS
$286M 13.75%
3,108,808
+707,691
+29% +$61.2M
ABMD
3
DELISTED
Abiomed Inc
ABMD
$262M 12.61%
2,827,005
+84,700
+3% +$7.46M
UTHR icon
4
United Therapeutics
UTHR
$23B
$200M 9.62%
1,524,254
+84,326
+6% +$13.5M
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$12.6B
$176M 8.44%
1,666,492
+6,400
+0.4% +$855K
AMAG
6
DELISTED
AMAG Pharmaceuticals
AMAG
$110M 5.31%
2,777,392
+585,251
+27% +$36.3M
INSM icon
7
Insmed
INSM
$29B
$88.6M 4.26%
4,768,800
+35,199
+0.7% +$879K
KYTH
8
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$84.4M 4.06%
1,125,564
-164,728
-13% -$12.3M
ENDP
9
DELISTED
Endo International plc
ENDP
$55.5M 2.67%
801,230
-63,374
-7% -$5.07M
VNDA icon
10
Vanda Pharmaceuticals
VNDA
$298M
$45.1M 2.17%
3,997,108
+99,700
+3% +$1.22M
WMGI
11
DELISTED
Wright Medical Group Inc
WMGI
$43.2M 2.08%
2,056,251
– –
KPTI icon
12
Karyopharm Therapeutics
KPTI
$44.6M
$32.5M 1.56%
205,716
+90,281
+78% +$24.1M
PRTA icon
13
Prothena Corp
PRTA
$444M
$31.6M 1.52%
695,918
– –
GILD icon
14
Gilead Sciences
GILD
$165B
$31.1M 1.5%
316,900
+17,400
+6% +$1.93M
CELG
15
DELISTED
Celgene Corp
CELG
$29.3M 1.41%
270,800
+8,600
+3% +$1.07M
FOLD
16
DELISTED
Amicus Therapeutics
FOLD
$27.6M 1.33%
1,974,376
– –
EPZM
17
DELISTED
Epizyme, Inc
EPZM
$27.2M 1.31%
2,115,638
+2,054,373
+3,353% +$41.5M
MNTA
18
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$23.9M 1.15%
1,455,176
– –
MDVN
19
DELISTED
MEDIVATION, INC.
MDVN
$21.7M 1.04%
509,862
+149,262
+41% +$7.39M
SHPG
20
DELISTED
Shire pic
SHPG
$21.5M 1.03%
104,700
+6,400
+7% +$1.52M
STAA icon
21
STAAR Surgical
STAA
$1.25B
$20.5M 0.99%
2,642,922
– –
ZLTQ
22
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$18.2M 0.88%
568,436
– –
SQNM
23
DELISTED
SEQUENOM INC NEW
SQNM
$17.5M 0.84%
10,023,842
– –
THOR
24
DELISTED
THORATEC CORPORATION
THOR
$17M 0.82%
268,861
-2,291,442
-89% -$136M
ISRG icon
25
Intuitive Surgical
ISRG
$135B
$13.4M 0.64%
261,900
-29,250
-10% -$1.66M
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
GPSPJS
General Pension Society PZU Joint Stock Warsaw, Poland $654M AUM 55.85% 1-Year Est. Return
W
WPWealth Fort Worth, Texas $654M AUM 13.19% 1-Year Est. Return
DAS
Diversify Advisory Services Sandy, Utah $655M AUM 24.57% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return

Palo Alto Investors's Q3 2015 Portfolio in Review

As of Q3 2015, Palo Alto Investors held 49 positions worth $2.08B, down 7.5% from $2.25B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Palo Alto Investors's Q3 2015 filing shows 4 new, 17 increased, 7 reduced and 2 closed positions. Its largest new stake was Aimmune Therapeutics: 325,599 shares worth $8.24M. The largest sale was THORATEC CORPORATION, an estimated $136M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 69% a quarter earlier.

  • Palo Alto Investors's largest Q3 2015 buy was Aimmune Therapeutics: 325,599 shares worth $8.24M.
  • Palo Alto Investors added most to Clovis Oncology, Inc. in Q3 2015, an estimated $61.2M increase.
  • Palo Alto Investors's biggest Q3 2015 reduction was THORATEC CORPORATION, cutting an estimated $136M.
  • Palo Alto Investors fully exited CYBERONICS INC in Q3 2015, selling an estimated $24.5M.
  • Palo Alto Investors's ten largest holdings make up 77% of its $2.08B portfolio in Q3 2015.
  • Palo Alto Investors opened 4 new positions and closed 2 in Q3 2015.
  • Palo Alto Investors's portfolio value fell 7.5% quarter-over-quarter to $2.08B.

Based on Palo Alto Investors's 13F filing for Q3 2015, filed 16 Nov 2015.